Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lithium + ziprasidone
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of lithium (a mood stabilizer) and ziprasidone (an atypical antipsychotic). This combination is primarily used for the maintenance treatment of bipolar disorder, particularly for patients who continue to experience inadequate control of manic or mixed symptomatology with lithium monotherapy. Ziprasidone works as a dopamine D2 and serotonin 5HT2A antagonist with serotonin reuptake inhibition properties, while lithium acts as a mood stabilizer. The combination was approved by the FDA in 2009 for maintenance treatment in bipolar disorder.
02
Targets
DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on lithium + ziprasidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lithium + ziprasidone.